UiPath (NYSE:PATH – Get Rating) had its price objective upped by stock analysts at BMO Capital Markets from $16.00 to $20.00 in a research report issued on Friday, The Fly reports. BMO Capital Markets’ price objective points to a potential upside of 17.30% from the stock’s previous close.
Several other equities research analysts also recently commented on the company. Morgan Stanley boosted their target price on UiPath from $15.00 to $16.00 and gave the stock an “equal weight” rating in a report on Thursday. Wells Fargo & Company upped their target price on shares of UiPath from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Thursday. Barclays raised their price target on shares of UiPath from $13.00 to $17.00 and gave the company an “equal weight” rating in a research report on Thursday. JPMorgan Chase & Co. upped their price objective on UiPath from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Thursday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $20.00 target price on shares of UiPath in a report on Thursday. Eight investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $19.19.
UiPath Stock Down 1.0 %
Shares of PATH opened at $17.05 on Friday. UiPath has a 52 week low of $10.40 and a 52 week high of $31.88. The stock has a market cap of $9.43 billion, a P/E ratio of -28.42 and a beta of 0.60. The business’s 50 day moving average price is $15.06 and its 200-day moving average price is $13.60.
Insider Transactions at UiPath
Institutional Trading of UiPath
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Motley Fool Asset Management LLC raised its position in shares of UiPath by 5.3% during the 2nd quarter. Motley Fool Asset Management LLC now owns 12,148 shares of the healthcare company’s stock valued at $250,000 after purchasing an additional 607 shares during the period. Creative Planning raised its holdings in UiPath by 7.0% during the second quarter. Creative Planning now owns 10,163 shares of the healthcare company’s stock valued at $185,000 after acquiring an additional 666 shares during the period. Voya Investment Management LLC lifted its position in shares of UiPath by 1.2% in the fourth quarter. Voya Investment Management LLC now owns 58,567 shares of the healthcare company’s stock valued at $744,000 after acquiring an additional 719 shares in the last quarter. Advisors Asset Management Inc. boosted its stake in shares of UiPath by 11.6% in the second quarter. Advisors Asset Management Inc. now owns 7,249 shares of the healthcare company’s stock worth $132,000 after acquiring an additional 754 shares during the period. Finally, Royal London Asset Management Ltd. grew its position in shares of UiPath by 0.9% during the second quarter. Royal London Asset Management Ltd. now owns 92,324 shares of the healthcare company’s stock worth $1,683,000 after purchasing an additional 811 shares in the last quarter. Hedge funds and other institutional investors own 56.40% of the company’s stock.
UiPath Company Profile
UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.
- Get a free copy of the StockNews.com research report on UiPath (PATH)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.